Objective: Fetal myelomeningocele (fMMC) surgery improves infant outcomes when compared with postnatal surgery. Surgical selection criteria and the option of pregnancy termination, however, limit the number of cases that are eligible for prenatal surgery. We aimed to quantify what proportion of cases could ultimately benefit from fetal therapy.
| INTRODUCTION
Fetal myelomeningocele (fMMC) is a common congenital central nervous system anomaly with an incidence of approximately 3-4 per 10 000 live births in countries with folic acid supplementation programs. 1 The condition has an 8% infant mortality rate 2 and leads to considerable morbidity, with lifetime healthcare costs exceeding $600 000 (2002 US dollars) amongst survivors. 3 Typically, spina bifida Since the publication of the MOMS trial, the number of centers offering fMMC surgery has increased significantly, particularly in the USA, thereby increasing regional access, but potentially diluting the expertise of individual centers. Although there are no good data to support how many centers are needed and what a minimal number of cases per center should be to ensure competency, it is important to note that the total number of women undergoing fMMC surgery will likely be much smaller than the total number of cases of fMMC as many couples will still choose to terminate the pregnancy or to continue the pregnancy with postnatal treatment for several reasons. For example, the surgery is typically reserved for healthy mothers and singleton fetuses without associated structural or genetic anomalies, similar to the selection criteria used in the MOMS trial. 4, 5 Additionally, not all patients who are surgical candidates will consent to the procedure, as the surgery has significant risks, both for the index pregnancy and for future pregnancies, 6, 7 and entails significant lifestyle modifications (eg, relocation for the surgery and limited physical activity) with potential financial implications.
The aim of this study was to estimate the number of cases of fMMC that would be candidates for fMMC repair in Canada and to estimate how many of those would likely opt for the procedure. was recorded.
| METHODS
For each case, we assessed potential eligibility for fMMC surgery using the same inclusion and exclusion criteria as in the MOMS study. 
| Statistics
Statistical analysis was carried out using Prism for Windows version for ineligibility" were compared between patients who continued the pregnancy and those who terminated using Fisher's exact test.
| RESULTS
We retrieved a total of 158 pregnancies complicated by fMMC. We have seen an important increase in the number of referrals since the
What is already known about this topic?
• Typically, fetal myelomeningocele is treated postnatally, but since 2011, antenatal surgery has become a clinical option.
What does this study add?
• Availability of a national fetal surgery program increases the uptake of fetal surgery for fetal myelomeningocele compared with international referral.
• After exclusion of cases for surgical reasons or because the parents opt to terminate the pregnancy, 29% of cases is ultimately eligible for fetal surgery.
• We provide numbers that allow estimating the need for local fetal surgery programs for fetal myelomeningocele.
These numbers can be extrapolated to other countries but will need to be adjusted for disease incidence and pregnancy termination rates, which vary regionally.
start of our fMMC surgery program in June 2017, with 26 cases seen over a 9-month period, whereas annual numbers fluctuated between seven and 18 cases per year prior to that.
Baseline characteristics are presented in Table 1 Details on the index pregnancy are listed in Table 1 . There was an overrepresentation of multiple pregnancies with an incidence of 9.5% (14 twins, one triplet pregnancy). Diagnosis was typically made at the time of the anatomy screening ultrasound with mean gestational age (GA) at diagnosis of 19.9 ± 3.0 weeks. Eighty-three percent of lesions were at a lumbar level. Sixty percent (n = 95) of our study population had ventriculomegaly. Out of those cases, mild (10-12 mm), moderate (12-14.9 mm), and severe ventriculomegaly (≥15 mm) were seen at presentation in 41.1%, 30.5%, and 28.4% of cases, respectively. In total, 31 fetuses (20%) had other anomalies unrelated to the MMC on ultrasound (Table 2) .
Fetal karyotyping or chromosomal microarray were available for 150 fetuses (95%), either from amniocentesis or postnatal testing.
Abnormal results were identified in 11 fetuses (7%): six cases of trisomy 18, two cases of triploidy, one case of trisomy 13, and two cases of pathogenic copy-number variants on microarray results, 10 of whom had additional anomalies detected on ultrasound (Table 3 ).
In the total cohort of 158 cases, 83 (53%) opted for termination of pregnancy. Of the remaining 75, 46 (which is 29% of the initial cohort of 158) were potential candidates for fetal surgery. Reasons for exclusion from fMMC surgery are presented in Table 4 .
Forty-seven cases were seen prior to the publication of the MOMS trial (2008) (2009) (2010) . In this subgroup, 30 (64%) would have been eligible for fetal surgery, and 18 of those (60%) elected to stop the pregnancy, leaving 12 potential surgical candidates (26% of the initial cohort). The termination rate amongst ineligible cases was 53%
(n = 9 of 17). 
| DISCUSSION
In this large series of fMMC cases from a Canadian tertiary referral center, we demonstrate that, after exclusion of ineligible cases and those opting for pregnancy termination, nearly one-third were potential candidates for fetal surgery.
The main reasons for exclusion from fMMC surgery were associated fetal anomalies and abnormal karyotype results. As expected, these findings were also associated with a higher pregnancy termination rate. In comparison with the MOMS trial, we had a similar number of exclusions for previous preterm birth (3.7% vs 3.6% in MOMS) 4 but lower exclusion rates for a high BMI (6% vs 10%) or significant maternal morbidity (0% vs 4.5%).
Actual uptake of fMMC surgery amongst eligible cases was 18%
when it required a cross-border referral but increased to 75% when the intervention became available locally. The latter number is much higher than that reported by Ovaere et al 9 and by Mazzone et al However, an increase in uptake of care is also expected to take place when care becomes available locally, as international travel for care, with its associated financial costs and family disruption, will dissuade many patients from opting for fMMC repair. We also expect to see a further increase in uptake of fMMC surgery if a minimally invasive fetoscopic approach, which has a potential to reduce maternal morbidity, becomes available. 12, 13 We saw an apparent decrease in pregnancy termination rates amongst patients eligible for surgery since the introduction of our program. This finding might reflect a referral bias, if only cases planning to continue the pregnancy and motivated to undergo fMMC surgery were actually referred. These changes in termination rates, however, may also be the result of a change in patient perception. We nevertheless strongly try to avoid presenting the surgery as an alternative to pregnancy termination, 14 but rather as an additional option for those who have decided to continue the pregnancy, as the residual risks for ventriculo-peritoneal shunting and motor dysfunction remain high, 15 and the effect on bladder function is still unclear. In summary, we here provide numbers that allow to estimate the need for local fetal surgery programs for fMMC. These numbers can be extrapolated to other countries but will need to be adjusted for baseline MMC incidence and pregnancy termination rates, both of which can vary regionally. Total number of patients who had uterine anomalies was three but only two patients were excluded as one patient underwent a hysteroscopic uterine excision.
